Literature DB >> 16648795

Involvement of cannabinoid CB1 and CB2 receptor activity in the development of behavioural sensitization to methamphetamine effects in mice.

Leos Landa1, Alexandra Sulcova, Karel Slais.   

Abstract

OBJECTIVES: An increased behavioural response ("behavioural sensitization") to drugs of abuse occurs after repeated treatment. In the present study the possibility of cross-sensitization existence between various cannabinoid receptor ligands--CB1 agonist methanandamide, CB2 agonist JWH 015, and CB1 antagonist AM 251 with methamphetamine was explored.
METHODS: Locomotion in the open field was measured in naive mice and in those pre-treated acutely and repeatedly (for 8 days), respectively, with either vehicle or tested drugs.
RESULTS: Methamphetamine produced significant sensitization to its stimulatory effect on locomotion. Methanandamide pre-treatment elicited cross-sensitization to methamphetamine effect, whereas pre-treatment with JWH 015 did not. Combined pre-treatment with methamphetamine+AM 251 suppressed sensitization to methamphetamine.
CONCLUSIONS: These results suggest that the activity of the endocannabinoid system is involved in the neuronal circuitry underlying the development of sensitization to methamphetamine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16648795

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  9 in total

1.  Behavioral effects of psychostimulants in mutant mice with cell-type specific deletion of CB2 cannabinoid receptors in dopamine neurons.

Authors:  Ana Canseco-Alba; Norman Schanz; Branden Sanabria; Juan Zhao; Zhicheng Lin; Qing-Rong Liu; Emmanuel S Onaivi
Journal:  Behav Brain Res       Date:  2018-11-30       Impact factor: 3.332

2.  Neural encoding of psychomotor activation in the nucleus accumbens core, but not the shell, requires cannabinoid receptor signaling.

Authors:  Joshua T Morra; Stanley D Glick; Joseph F Cheer
Journal:  J Neurosci       Date:  2010-04-07       Impact factor: 6.167

3.  Local pretreatment with the cannabinoid CB1 receptor antagonist AM251 attenuates methamphetamine intra-accumbens self-administration.

Authors:  Jesse S Rodriguez; Sherin Y Boctor; Luke C Flores; Clyde F Phelix; Joe L Martinez
Journal:  Neurosci Lett       Date:  2010-12-15       Impact factor: 3.046

Review 4.  Pharmacological approaches to methamphetamine dependence: a focused review.

Authors:  Laurent Karila; Aviv Weinstein; Henri-Jean Aubin; Amine Benyamina; Michel Reynaud; Steven L Batki
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

5.  The cannabinoid CB1 receptor antagonist AM251 does not modify methamphetamine reinstatement of responding.

Authors:  Sherin Y Boctor; Joe L Martinez; Wouter Koek; Charles P France
Journal:  Eur J Pharmacol       Date:  2007-06-13       Impact factor: 4.432

6.  Decreased frontal N-acetylaspartate levels in adolescents concurrently using both methamphetamine and marijuana.

Authors:  Young-Hoon Sung; Paul D Carey; Dan J Stein; Helen L Ferrett; Bruce S Spottiswoode; Perry F Renshaw; Deborah A Yurgelun-Todd
Journal:  Behav Brain Res       Date:  2013-03-04       Impact factor: 3.332

7.  Δ9-tetrahydrocannabinol prevents methamphetamine-induced neurotoxicity.

Authors:  M Paola Castelli; Camilla Madeddu; Alberto Casti; Angelo Casu; Paola Casti; Maria Scherma; Liana Fattore; Paola Fadda; M Grazia Ennas
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240

8.  Caveolin-1 Expression in the Dorsal Striatum Drives Methamphetamine Addiction-Like Behavior.

Authors:  Yosef Avchalumov; Alison D Kreisler; Wulfran Trenet; Mahasweta Nayak; Brian P Head; Juan C Piña-Crespo; Chitra D Mandyam
Journal:  Int J Mol Sci       Date:  2021-07-30       Impact factor: 6.208

9.  Adolescent cannabinoid exposure induces irritability-like behavior and cocaine cross-sensitization without affecting the escalation of cocaine self-administration in adulthood.

Authors:  Jenni Kononoff; Philippe A Melas; Marsida Kallupi; Giordano de Guglielmo; Adam Kimbrough; Maria Scherma; Paola Fadda; Denise B Kandel; Eric R Kandel; Olivier George
Journal:  Sci Rep       Date:  2018-09-17       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.